doi: 10.1210/clinem/dgaa863 Summary Keywords obesity, insulin-resistance, Tirzepatide, pathophysiology, GIP, GLP - 1, clinical trials, arterial hypertension Citation Corrao S, Pollicino C, Maggio D, Torres A and Argano C (2024) Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
2jm), only treatment with tesaglitazar, but not (equimolar doses of) GLP-1RA or GLP-1RA/tesaglitazar, reduced plasma cholesterol levels (Fig
Keranis E, Makris D, Rodopoulou P, et al
For decades, pharma companies have been searching for the commercial holy grail: a drug that is both safe and effective for weight loss
Are you sharp
Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation